Treatment of carcinoma in situ of the bladder with doxorubicin (adriamycin).
Fifty-five patients with carcinoma in situ of the bladder have been treated with intravesical Adriamycin, the longest follow-up being over 2.5 years. Side-effects were negligible. Primary carcinoma in situ shows the highest overall response rate, with over 80%, followed by secondary carcinoma in situ with no tumours, with 67%; in the presence of active tumour only 25% of patients treated showed any real improvement. Adriamycin is recommended for the conservative management of primary carcinoma in situ.
D002278:Carcinoma in Situ / Q000188:drug therapy* / Q000556:secondary; D003558:Cystoscopy; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000556:secondary
D004317:Doxorubicin